InVitria Launches Optibumin® 25, the First Recombinant 25% Human Serum Albumin for Closed-System Biomanufacturing
JUNCTION CITY, Kan.--(BUSINESS WIRE)--InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin (rHSA) available as a 25% solution. Designed for closed-system workflows, Optibumin 25 is a high-purity alternative to plasma-derived albumin, enabling safer, more consistent manufacturing in cell and gene therapy applications.
Optibumin® 25 is the first recombinant 25% human serum albumin for closed-system biomanufacturing, offering consistency, sterility, and GMP compliance.
Share
For decades, plasma-derived HSA has presented regulatory and supply chain challenges, including batch variability and pathogen risks. Optibumin 25 eliminates these issues by offering a chemically defined, animal-origin-free, GMP-compliant alternative. It supports regulatory compliance while improving scalability, sterility, and formulation performance.
'Optibumin 25 directly replaces plasma-derived 25% HSA while enhancing process control and reducing regulatory risk,' said Scott Deeter, CEO at InVitria. 'It enables the kind of consistency required for clinical and commercial-scale production.'
Manufactured in an ISO 9001-certified, cGMP-compliant facility, Optibumin 25 is optimized for downstream processing, formulation, and cryopreservation workflows. The product is currently available in 100 mL single-use bags and is suitable for integration into viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.
Key Benefits:
First recombinant 25% HSA designed for closed systems
Animal-origin-free and chemically defined
GMP-ready and scalable to commercial volumes
Stable, sterile, and contamination-resistant
To learn more visit:
www.invitria.com/optibumin25
About InVitria
InVitria develops and manufactures high-performance, animal-origin-free supplements and excipients that support regulatory compliance and product consistency in biologics manufacturing. Its recombinant portfolio enables safer, scalable alternatives to blood-derived materials in cell and gene therapy, vaccine development, and regenerative medicine. InVitria products are manufactured in the United States in cGMP-compliant, ISO 9001-certified facilities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
24 minutes ago
- Business Upturn
SBI Life Insurance Relaxes Claim Documentation Requirements for Victims of Tragic AI 171 Plane Crash in Ahmedabad
By Business Wire India Published on June 14, 2025, 11:59 IST Mumbai, Maharashtra, India: SBI Life has simplified claims processes, as a measure to aid families of victims of the tragic AI 171 plane crash in Ahmedabad on June 12, 2025. Understanding the overwhelming emotional strain that arise from procedural challenges in such situations, SBI Life has eased the claim process to offer faster financial assistance. SBI Life will not insist on submission of death certificate from the claimant. SBI Life will consider evidence of death from an official government record or entries from governmental portals, municipal records or e-governance databases as proof of death. Claim can be intimated with minimum documents like claim form, Policy Document and details of KYC and bank account of the nominee. Further, family members can also call on SBI Life's 24×7 toll free number at 1800 267 9090 for any claims queries. 'At SBI Life, we stand in solidarity with the families impacted by this unfortunate tragedy. In these moments of deep loss, our priority is to compassionately ensure a swift and simplified claim settlement experience,' said the co mpany. Families and nominees of policyholders affected by the crash are encouraged to connect with the nodal officer or connect with the nearest SBI Life branch or reach out to SBI Life's dedicated customer support for assistance with claims. District Nodal Officer Contact details Senior Nodal Officer Contact details Ahmedabad Mr. Kinner Pandya Email id: [email protected] Landline: 079-66103317 Mr. Virendra Chauhary Email id: [email protected] Landline: 079-66103342 Email: [email protected] Call on Toll-Free Number: 1800 267 9090 (customer servicing timing: 24×7) Vi sit the nearby SBI Life Branch for any assistance SBI Life expresses deep sorrow over the loss of lives in the crash and reiterates its commitment to standing by the families during this time of grief. Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
4 hours ago
- Business Upturn
Sun Pharma's Halol facility receives form 483 with 8 observations from US FDA
By Aman Shukla Published on June 14, 2025, 09:42 IST Sun Pharmaceutical Industries Limited, one of India's leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) at its Halol manufacturing facility located in Gujarat, India. The inspection was conducted from June 2 to June 13, 2025, as part of the regulatory authority's routine evaluation of current Good Manufacturing Practices (GMP) compliance. At the end of the inspection, the US FDA issued a Form 483 to the company, outlining eight observations. In a regulatory filing, Sun Pharma stated: 'We hereby inform that the US FDA conducted a GMP inspection of our Halol facility from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483 with 8 observations.' A Form 483 is issued by the US FDA when its investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related regulations. These observations are based on conditions found during routine inspections and are intended to prompt the company to take corrective actions. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
7 hours ago
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
